Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27.2M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
18.9M
-
Shares change
-
-4.04M
-
Total reported value, excl. options
-
$40.7M
-
Value change
-
-$19.6M
-
Put/Call ratio
-
13.27
-
Number of buys
-
19
-
Number of sells
-
-32
-
Price
-
$2.15
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q3 2024
85 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q3 2024.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.9M shares
of 27.2M outstanding shares and own 69.65% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (2.75M shares), Siren, L.L.C. (2.59M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.07M shares), Samsara BioCapital, LLC (1.79M shares), Point72 Asset Management, L.P. (1.47M shares), Flagship Pioneering Inc. (1.29M shares), Avidity Partners Management LP (1.06M shares), VANGUARD GROUP INC (953K shares), Deep Track Capital, LP (828K shares), and Opaleye Management Inc. (655K shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.